Clinical Trials Browser

Completed × Bevacizumab × Dermatologic × Clear all

NCT01950390 2025-12-11

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

169 enrolled 14 charts

Melanoma

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1 Completed

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT04091217 2024-10-24

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Phase 2 Completed

43 enrolled 12 charts

Melanoma

NCT00790010 2023-05-11

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Phase 1 Completed

Melanoma

NCT00591734 2021-11-24

RAD001 Plus Bevacizumab in Metastatic Melanoma

Phase 2 Completed

57 enrolled 7 charts

Melanoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

24 enrolled 10 charts

Uveal Melanoma, Melanoma

NCT01069627 2018-12-06

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Phase 2 Completed

20 enrolled 21 charts

Melanoma

NCT00074308 2018-06-20

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Phase 1/2 Completed

40 enrolled 10 charts

Melanoma

NCT00626405 2018-05-01

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

95 enrolled 8 charts

Melanoma

NCT00387751 2017-11-22

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase 2 Completed

14 enrolled 5 charts

Melanoma

NCT00434252 2017-07-18

BEAM

Phase 2 Completed

214 enrolled 15 charts

Melanoma

NCT00397982 2017-06-09

Mel47

Phase 2 Completed

17 enrolled 12 charts

Melanoma

NCT00976573 2017-04-04

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Phase 2 Completed

149 enrolled 9 charts

Melanoma

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00026221 2016-03-17

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Phase 2 Completed

57 enrolled 9 charts

Melanoma

NCT00139360 2015-08-27

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00959647 2015-01-07

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Phase 2 Completed

19 enrolled 7 charts

DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

NCT00462423 2014-01-08

AbraxAvast

Phase 2 Completed

50 enrolled 10 charts

Melanoma

NCT01743157 2013-08-29

BBI

Phase 1/2 Completed

Melanoma

NCT00568048 2013-04-10

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Completed

Melanoma

NCT01048554 2012-04-19

MEL0107

Phase 2 Completed

Melanoma

NCT00734890 2012-03-16

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasmThoracic

Adenocarcinoma of Lung, Burkitt Lymphoma, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT00308607 2009-04-03

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Phase 2 Completed

Melanoma, Neoplasm Metastasis